We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase-II study.
- Authors
Metzgeroth, Georgia; Walz, Christoph; Erben, Philipp; Popp, Helena; Schmitt-Graeff, Annette; Haferlach, Claudia; Fabarius, Alice; Schnittger, Susanne; Grimwade, David; Cross, Nicholas C. P.; Hehlmann, Rüdiger; Hochhaus, Andreas; Reiter, Andreas
- Abstract
This study evaluated the efficacy and safety of imatinib in chronic eosinophilic leukaemia (CEL, n = 23) and hypereosinophilic syndrome (HES, n = 13). In CEL with FIP1L1-PDGFRA ( n = 16) or various PDGFRB fusion genes ( n = 5), complete haematological remission (CHR) was achieved in 95% (20/21) after 3 months. Complete molecular remission (CMR) was seen in 75% (12/16) of cases with FIP1L1-PDGFRA positive CEL by 6 months, and in 87% (13/15) after 12 months. CMR was achieved in three of five PDGFRB fusion positive patients after 3, 9 and 18 months respectively. All patients are currently on imatinib (100 mg; n = 13, 400 mg; n = 8) and no molecular relapse has yet been observed (median 26·7 months; range, 6·9–39·9). Imatinib was less effective in HES and CEL without known molecular aberration ( n = 15); CHR was observed in 40% (6/15) of patients, two patients relapsed after 4·8 and 24·5 months. Three patients died due to imatinib-resistant progressive CEL ( n = 2) or myocardial infarction ( n = 1) unrelated to study treatment. Overall, imatinib was well tolerated with a low incidence of grade III/IV toxicities. These data confirmed the long-term efficacy of imatinib for PDGFR-rearranged CEL patients, and also showed that a minority of HES cases without known molecular aberrations may benefit from imatinib.
- Subjects
LEUKEMIA; IMATINIB; EOSINOPHILIC granuloma; CORONARY disease; PHYSICAL &; theoretical chemistry
- Publication
British Journal of Haematology, 2008, Vol 143, Issue 5, p707
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2008.07294.x